| March 3-10, 2014
Quote of the Day...
"It’s a pandemic, and there is an urgent need for cheap, effective, user-friendly anti-HCV oral drugs that can be given to the sickest and poorest people in the world. We have a moral obligation to do something about it as quickly as possible."
... to Erica Johnson for winning the Best Abstract award at HIV Science 2014 (Chennai, India) in January. Erica is receiving her award from Francois Barre-Sinoussi, winner of the 2008 Nobel Prize for isolating HIV. Also in the picture are Jack Whitescarver, Director of the NIH Office of AIDS Research, and Suniti Solomon – organizer of the conference and India's most eminent HIV provider and investigator. Other authors on the abstract are CFAR's Hin Chu, Sid Byrareddy, Paul Spearman, and Rana Chakraborty.
Read Erica's award winning abstract
| || |
... to NIH/NIAID and NIH/NIMH for releasing so many new HIV/AIDS-related funding opportunities (see New Listings sections in Funding Opps below) and for increasing the scope of previous ones. Of particular note is a significant expansion of the scientific scope of "Targeting Persistent HIV Reservoirs" to now allow for basic research into the cellular and molecular mechanisms of HIV latency and persistence. Turnaround time to take advantage of this expanded opportunity is short though. LOI deadline: March 25, Application deadline: April 25, 2014.
In other news...
• Read a summary of the specific changes / expansions to PAR-12-109
• Read the complete RFA.
... to Bill Lewis (March 7) and Effie Bartley (March 8).
The year you were born only marks your entry into the world. The years where you prove your worth, they are the ones worth celebrating."
― Jarod Kintz
... Twenty seven CFARians will be representing the research of 60 CFAR investigators at CROI this week. This includes 9 orals, 28 posters and a lot of VERY exciting science.
Here's a "CFAR Does CROI" guide to help you get around
... Andy Riess, Assistant Director of outreach for the Fulbright Scholar Program will conduct a workshop (March 3, 2:30–4:00pm, Math & Science Center Room E208) for Emory faculty on applying for Fulbright grants.
The workshop will cover teaching and research opportunities in more than 125 countries, tips on preparing your application, opportunities to host visiting Fulbright scholars at Emory, and advice on making contacts abroad. The deadline for applications to the 2015-2016 Fulbright Scholar Program is August 1.
Register to Attend
Katelyn Sturdivant is seeking a position as a lab assistant. She has skills in JMP/JMP Genomics, GNU Image Manipulation Program (GIMP) and CITI certifications in biomedical investigation and good clinical practice.
• Katelyn's CV
LGBTQ, Transgender, Latino/Latina Individuals Wanted:
The City of Atlanta (Fulton/DeKalb Counties) Jurisdictional HIV Prevention Planning Group (JPPG) is looking for new members who can assist in maintaining a qualified and diverse planning group reflective of the HIV epidemic in Fulton and DeKalb counties. JPPG membership is contingent on being present at six half-day plenary meetings a year and on serving on at least one JPPG sub-committee.
• JPPG brochure
• Application (Deadline: March 31).
Virologically Supressed HIV+ Study Participants Wanted:
The purpose of this study is to evaluate safety and to determine whether E/C/F/TAF STR plus Darunavir (DRV) is effective against HIV-1 in subjects on current antiretroviral regimens (ARV) in virologically suppressed, HIV-1 positive subjects.
• Study Flier
HIV- Female Study Participants Wanted:
Ameeta Kalokhe is seeking HIV negative study participants who have, in the last 5 years, met one or more of the following criteria: Used IV drugs, cocaine, crack, or
meth | Had an STI | Had unprotected sex with more than 4 men | Had protected sex with more than 6 men
| Had sex with a known HIV+ man
| Had sex in exchange for drugs, money, or shelter
| Been with a partner that meets any of the above
• Study Flier
Elite Controller Study Participants Wanted:
Seeking HIV+ men and women who are naturally controlling their virus, in order to study the effects and potential benefit of ART in this population. The study is a prospective, single-arm, open-label study to evaluate the effect of fixed-dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-cell activation, absolute CD4+ T-Cell count, inflammatory biomarkers and viral reservoir in treatment-naïve HIV-1 controllers [ACTG A5308].
• Study Flier